Absolute neutrophil count (ANC) >= 1000/mm^3 (after granulocyte colony-stimulating factor [G-CSF] discontinued)
The absolute neutrophil count (ANC) >= 1000/mm^3 without colony stimulating factor support
Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: Absolute neutrophil count (ANC) ?1500 cells/mm3, Platelet count ?100 x 109/L, Hemoglobin (Hgb) ?10 g/dL
Absolute neutrophil count >= 1000/mm^3 without colony stimulating factor support, within 14 days before the first dose of cabozantinib
The absolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support within 7 days before the first dose of cabozantinib
Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl, within 14 days prior to registration; this ANC cannot have been induced by granulocyte colony stimulating factors
Absolute neutrophil count >= 1000/uL without growth factor support (e.g. granulocyte colony stimulating factor [GCSF]) in the previous 7 days
Neutrophil count ? 1,500/mm3 without granulocyte colony stimulating factor.
Obtained within 28 days prior to the first dose of cabozantinib: absolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support.
Within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,000/mcl; this ANC cannot have been induced by granulocyte colony stimulating factor
Absolute neutrophil count (ANC) >= 1000 x 10^9/L, unsupported by granulocyte colony-stimulating factor (G-CSF) or granulocytes (within 14 days of study registration)
Within 7 days before the first dose of study treatment: The absolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support
Absolute neutrophil count (ANC) < 1500 cells/uL (granulocyte colony-stimulating factor support should not be used within 2 weeks prior to cycle 1, day 1)
Absolute neutrophil count > 750 cells/mm^3 (0.75 x 10^9/L) independent of transfusion and growth factor support for at least 7 days prior to screening (except for pegylated granulocyte-colony stimulating factor [G-CSF] [pegfilgrastim] and darbepoetin which require at least 14 days prior to screening)
FULL STUDY INCLUSION CRITERIA: Absolute neutrophil count (ANC) >= 1000/mm^3, without biologic response modifiers, such as granulocyte colony-stimulating factor (G-CSF), within 6 weeks before the start of study treatment
Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: Absolute neutrophil count (ANC) ?1500 cells/mm3, Platelet count ?100 x 109/L, Hemoglobin ?10 g/dL; subjects with thalassemia having a hemoglobin <10 g/dL may be enrolled, per Investigator discretion
Absolute neutrophil count (ANC) >= 1,500/mcl; this ANC cannot have been induced or supported by granulocyte colony stimulating factors
Absolute neutrophil count >= 1,500/mcL (without granulocyte colony-stimulating factor support within 2 weeks prior to cycle 1, day 1)
Adequate bone marrow function: WBC > 2000/?L; platelet count > 75,000/?L; Neutrophil count > 1000/?L, without use of colony stimulating factors (CSF).
Absolute neutrophil count (ANC) >= 1500 K/mm^3 (without use of granulocyte colony-stimulating factor [G-CSF] 4 weeks prior to enrollment)
Absolute neutrophil count (ANC) >= 1000/mcl (granulocyte-colony stimulating factor [G-CSF] is allowed) (must be within 7 days of MLA)
Within 4 days prior to the first dose of cabozantinib: Absolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support
Absolute neutrophil count (ANC) >= 1,500/mm^3 (no colony stimulating factor [CSF] support)
Absolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support
Peripheral absolute neutrophil count (ANC) >= 750/uL in absence of granulocyte colony stimulating factor (GCSF) for 72 hours (hrs) or pegylated (peg)-GCSF for 14 days
Absolute neutrophil count (ANC) ? 1.5 x 10^9/L without granulocyte colony-stimulating factor (G-CSF) support within 7 days preceding the lab assessment.
Absolute neutrophil count ? 1,500/mm3 (excluding measurements obtained within 7 days after administration of granulocyte colony-stimulating factor [G-CSF]).
RENAL COHORT: Laboratory values as follows within 4 days before the first dose of daratumumab: The absolute neutrophil count (ANC) ? 1500/mm^3 without colony stimulating factor support
BLADDER: Clinical laboratory values at screening: ANC ? 1500/mm^3 without colony stimulating factor support
Within 7 days before the first dose of cabozantinib: The absolute neutrophil count (ANC) >= 1000/mm^3 without colony stimulating factor support
Absolute neutrophil count (ANC) >= 1000/uL; granulocyte colony-stimulating factor receptor (G-CSF) is not permitted within 14 days of screening
Absolute neutrophil count (ANC) >= 500/mm^3 (patients should be off granulocyte colony-stimulating factor [G-CSF] for at least 7 days)
Absolute neutrophil count (ANC) >= 1500/mm^3, without colony stimulating factor support
Absolute neutrophil count (ANC) greater than or equal to 1,500/mm^3, equivalent to CTEP Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, grade 1; this ANC cannot have been induced or supported by granulocyte colony stimulating factors
Absolute neutrophil count >= 1,500/ul without colony stimulating factor support
Absolute neutrophil count >1000/mL (without a colony stimulating factor within the last 2 weeks)
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L without granulocyte colony-stimulating factor support, obtained within 14 days prior to initiation of study treatment
Absolute neutrophil count (ANC) ? 1.0 Ã— 109/L. Screening of ANC should be independent of granulocytecolony stimulating factor (G-CSF) support for at least one week and of pegylated G-CSF for at least two weeks.
Absolute neutrophil count (ANC) >= 1500/mm^3 (without use of granulocyte colony-stimulating factor [G-CSF] 4 weeks prior to enrollment)
Absolute neutrophil count (ANC) >= 1.0 x 10^9/L within 30 days prior to cycle 1 day 1, without granulocyte-colony stimulating factor (G-CSF)
Absolute neutrophil count (ANC) >= 1.0 x 10^9/L within 7 days of time of consent, without granulocyte- colony stimulating factor (G-CSF)
Absolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support
Absolute neutrophil count (ANC) greater than or equal to 1,500/ul, equivalent to Common Toxicity Criteria for Adverse Events v4.0 (CTCAE)  grade 1; this ANC cannot have been induced or supported by granulocyte colony stimulating factors
Absolute neutrophil count (ANC) >= 1000/mm^3, with or without granulocyte colony-stimulating factor (G-CSF) support; this requirement may be waived if the patient has hematologic relapse of disease or if patient has not yet recovered counts from chemotherapy
Platelet count >/=100,000 /mm3, hemoglobin >/=9 g/dL, absolute neutrophil count >/= 1500/mm3 without transfusions or granulocyte colony stimulating factor and other hematopoietic growth factors
Absolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support
Bone marrow function: Absolute neutrophil count (ANC) ? 1500 Cells/?L (with no evidence that this ANC was induced or supported by granulocyte colony stimulating factors)
Absolute neutrophil count (ANC) >= 1500 cells/uL (without granulocyte colony-stimulating factor support within 2 weeks prior to cycle 1, day 1)
Absolute neutrophil count (ANC) >= 1.0 x 10^9/L within 14 days prior to randomization independent of granulocyte colony-stimulating factor (G-CSF) for >= 1 week and pegylated G-CSF for >= 2 weeks
Absolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support
Absolute neutrophil count (ANC) greater than or equal to 1500/ul, equivalent to Common Toxicity Criteria for Adverse Events v3.0 (CTCAE) grade 1; this ANC cannot have been induced or supported by granulocyte colony stimulating factors
Engraftment of neutrophils (absolute neutrophil count [ANC] >= 1.0 X 10^9/L) for 3 days without granulocyte colony-stimulating factor (g-csf) support
Absolute neutrophil count (ANC) ? 1,500/?L without colony-stimulating factor support
Absolute neutrophil count (ANC) >= 1500/mm^3 (without granulocyte colony-stimulating factor [G-CSF] support within 2 weeks prior to cycle 1, day 1)
Absolute neutrophil count >= 1,000/mcL (in the absence of granulocyte colony stimulating factor (GCSF) for >= 14 days)
Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: ANC ?1500 cells/mm3, Platelet count ?100 x 109/L, Hemoglobin ?10 g/dL
